Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort

Fig. 6

Internally validated measures of model calibration. Plots show higher than expected survival probability at 6 months, slightly higher than expected survival at 1 year, and lower than expected survival probability at 2 years. Apparent: model based fit; Corrected: bootstrap corrected model fit; Ideal: Ideal fit

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us